Literature DB >> 9623511

IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.

S Partida-Sanchez1, L Favila-Castillo, S Pedraza-Sanchez, M Gomez-Melgar, A Saul, S Estrada-Parra, I Estrada-Garcia.   

Abstract

A group of 9 Mexican lepromatous leprosy patients was studied at the beginning of a type II reaction (erythema nodosum leprosum, ENL) and after 1 or 2 months of thalidomide treatment. ENL patients at the onset of the reaction had slightly higher amounts of anti-Mycobacterium leprae IgG1 and IgG2 antibodies, compared to similar lepromatous patients that did not develop ENL. Neither these antibody levels nor IgM and the other IgG subclasses were importantly modified after thalidomide treatment. Serum TNF was significantly higher in the patients that developed ENL compared to those that did not develop the reaction. TNF levels were slightly decreased after 1 month of thalidomide treatment and significantly decreased after 2 months of treatment. Serum IFN-gamma was significantly lower in patients at the onset of ENL and was increased after 1 and 2 months of thalidomide treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9623511     DOI: 10.1159/000023926

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  8 in total

1.  Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy.

Authors:  N Bahia El Idrissi; S Hakobyan; V Ramaglia; A Geluk; B Paul Morgan; P Kumar Das; F Baas
Journal:  Clin Exp Immunol       Date:  2016-03-31       Impact factor: 4.330

2.  Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day.

Authors:  Maria Stella de Mello Ayres Putinatti; Joel Carlos Lastória; Carlos Roberto Padovani
Journal:  An Bras Dermatol       Date:  2014 Mar-Apr       Impact factor: 1.896

3.  Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions.

Authors:  A Iyer; M Hatta; R Usman; S Luiten; L Oskam; W Faber; A Geluk; P Das
Journal:  Clin Exp Immunol       Date:  2007-11       Impact factor: 4.330

Review 4.  A Systematic Review of Immunological Studies of Erythema Nodosum Leprosum.

Authors:  Anastasia Polycarpou; Stephen L Walker; Diana N J Lockwood
Journal:  Front Immunol       Date:  2017-03-13       Impact factor: 7.561

Review 5.  The influence of innate and adaptative immune responses on the differential clinical outcomes of leprosy.

Authors:  Adriana Barbosa de Lima Fonseca; Marise do Vale Simon; Rodrigo Anselmo Cazzaniga; Tatiana Rodrigues de Moura; Roque Pacheco de Almeida; Malcolm S Duthie; Steven G Reed; Amelia Ribeiro de Jesus
Journal:  Infect Dis Poverty       Date:  2017-02-06       Impact factor: 4.520

6.  Guillain-Barre Syndrome: A Rare Presentation of Borderline Tuberculoid Leprosy with Type 1 Lepra Reaction.

Authors:  Deepa Dash; Alvee Saluja; Rajesh Kumar Singh; Rohit Bhatia; Manjari Tripathi
Journal:  J Neurosci Rural Pract       Date:  2018 Jul-Sep

7.  Thalidomide and discoid lupus erythematosus: case series and review of literature.

Authors:  Giovanna Malara; Chiara Verduci; Maria Altomonte; Maria Cuzzola; Caterina Trifirò; Cristina Politi; Giovanni Tripepi
Journal:  Drugs Context       Date:  2022-03-16

8.  Successful treatment by adding thalidomide to meglumine antimoniate in a case of refractory anthroponotic mucocutaneous leishmaniasis.

Authors:  Vahid Mashayekhi Goyonlo; Sadegh Vahabi-Amlashi; Faezeh Taghavi
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-08-27       Impact factor: 4.077

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.